DK1651666T3 - Alfavirus-baserede cytomegalovirusvacciner - Google Patents
Alfavirus-baserede cytomegalovirusvaccinerInfo
- Publication number
- DK1651666T3 DK1651666T3 DK04777706T DK04777706T DK1651666T3 DK 1651666 T3 DK1651666 T3 DK 1651666T3 DK 04777706 T DK04777706 T DK 04777706T DK 04777706 T DK04777706 T DK 04777706T DK 1651666 T3 DK1651666 T3 DK 1651666T3
- Authority
- DK
- Denmark
- Prior art keywords
- alphavirus
- replicon
- cytomegalovirus
- protein
- nucleic acid
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 241000701022 Cytomegalovirus Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 101900065606 Human cytomegalovirus Immediate early protein IE1 Proteins 0.000 abstract 1
- 108010021994 cytomegalovirus matrix protein 65kDa Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48650103P | 2003-07-11 | 2003-07-11 | |
PCT/US2004/021772 WO2005007689A1 (en) | 2003-07-11 | 2004-07-08 | Alphavirus-based cytomegalovirus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1651666T3 true DK1651666T3 (da) | 2009-08-31 |
Family
ID=34079236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04777706T DK1651666T3 (da) | 2003-07-11 | 2004-07-08 | Alfavirus-baserede cytomegalovirusvacciner |
Country Status (9)
Country | Link |
---|---|
US (1) | US7419674B2 (de) |
EP (1) | EP1651666B1 (de) |
AT (1) | ATE432285T1 (de) |
AU (1) | AU2004257214B2 (de) |
DE (1) | DE602004021260D1 (de) |
DK (1) | DK1651666T3 (de) |
ES (1) | ES2327643T3 (de) |
PT (1) | PT1651666E (de) |
WO (1) | WO2005007689A1 (de) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
JP4790984B2 (ja) | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
DK2290054T3 (en) * | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
ES2618309T3 (es) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
KR101454842B1 (ko) * | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
US7419674B2 (en) | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
CA2567254C (en) * | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
JP4896021B2 (ja) * | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
WO2006085983A2 (en) * | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
WO2007046839A2 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
US20100111992A1 (en) * | 2006-05-01 | 2010-05-06 | The Regents Of The University Of California | Cytomegalovirus peptides and methods of use thereof |
WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
AU2008266807B2 (en) | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
WO2009003493A2 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
ES2770335T3 (es) | 2010-07-06 | 2020-07-01 | Glaxosmithkline Biologicals Sa | Administración de ARN para desencadenar múltiples vías inmunológicas |
EP2591114B1 (de) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisierung grosser säugetiere durch niedrige dosen von rna |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
AU2011295935B2 (en) | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
PT2611467T (pt) | 2010-08-31 | 2022-08-01 | Glaxosmithkline Biologicals Sa | Lipossomas pequenos para entrega de arn que codifica um imunogénio |
KR102266691B1 (ko) * | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
JP2014522842A (ja) * | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
SG10201605537XA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
EP2729168A2 (de) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogene zusammensetzungen und ihre verwendungen |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
EP2766385A2 (de) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv-antigene und verwendungen davon |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
JP6232544B2 (ja) | 2011-11-11 | 2017-11-22 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | サイトメガロウイルスの治療のための組成物及び方法 |
JP6265344B2 (ja) | 2012-03-27 | 2018-01-24 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 抗サイトメガロウイルス中和抗体の検出方法 |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
EP3872097A1 (de) * | 2012-10-19 | 2021-09-01 | The Council Of The Queensland Institute Of Medical Research | Verbesserte immuntherapie gegen das humane herpesvirus |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
BE1023557B1 (fr) | 2014-02-10 | 2017-05-03 | Univercells Sa | Systeme, appareil et procede pour la production de biomolecules |
SG11201606625RA (en) * | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
US9925258B2 (en) | 2015-10-02 | 2018-03-27 | International Aids Vaccine Initiative | Replication-competent VSV-HIV Env vaccines |
JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
EP3364980A4 (de) | 2015-10-22 | 2019-07-10 | ModernaTX, Inc. | Nukleinsäure-impfstoffe für varicella zoster virus (vzv) |
AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3443107A1 (de) | 2016-04-13 | 2019-02-20 | Synthetic Genomics, Inc. | Rekombinante arterivirus-replikon-systeme und verwendungen davon |
CN109475579A (zh) * | 2016-05-23 | 2019-03-15 | 昆士兰医学研究所理事会 | Cmv表位 |
BR112019007433A2 (pt) | 2016-10-17 | 2019-07-02 | Synthetic Genomics Inc | sistemas de replicon de vírus recombinante e usos dos mesmos |
EP3528821A4 (de) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Impfstoff gegen das humane cytomegalovirus |
WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
AU2017372731B2 (en) | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
EP3551193A4 (de) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Nukleinsäureimpstoffe gegen atemwegsvirus |
EP3582790A4 (de) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Hochwirksame immunogene zusammensetzungen |
WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
US11883476B2 (en) | 2017-12-04 | 2024-01-30 | Intervet Inc. | Canine lyme disease vaccine |
US20200323975A1 (en) * | 2017-12-04 | 2020-10-15 | Intervet Inc. | Vaccination with replicon particles and oil adjuvant |
BR112020012049A2 (pt) * | 2017-12-18 | 2020-11-24 | Intervet International B.V. | vacina contra vírus da influenza a suína |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
EP3740245A4 (de) | 2018-01-19 | 2022-01-05 | Janssen Pharmaceuticals, Inc. | Auslösung und verstärkung von immunreaktionen unter verwendung rekombinanter replikonsysteme |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
US6770283B1 (en) | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
EP0716148B1 (de) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Rekombinanter Alphavirus Vektor |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
FR2723849B1 (fr) * | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
AU2809897A (en) * | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
US5726022A (en) | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
BR9713368A (pt) | 1996-11-20 | 2001-09-18 | Introgen Therapeutics Inc | Processo melhorado para a produção e a purificação de vetores adenovirais |
FR2757169B1 (fr) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US5958738A (en) | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
JP3692759B2 (ja) * | 1998-01-19 | 2005-09-07 | 株式会社デンソー | 車両用表示装置 |
GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
WO1999051263A2 (en) | 1998-04-08 | 1999-10-14 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
US7267823B2 (en) * | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
AU767551B2 (en) | 1998-06-29 | 2003-11-13 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
CA2336587A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
US6770479B1 (en) | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
CA2337966A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
CA2345440A1 (en) | 1998-10-05 | 2000-04-13 | Charles A. Nicolette | Genes differentially expressed in cancer cells to design cancer vaccines |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6242259B1 (en) | 1998-12-31 | 2001-06-05 | Chiron Corporation | Compositions and methods for packing of alphavirus vectors |
US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
EP2206785A1 (de) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel |
ATE463578T1 (de) | 1999-04-14 | 2010-04-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme |
ATE412763T1 (de) | 1999-08-31 | 2008-11-15 | Univ North Carolina | Antikörper-abhängige vergrösserung der alphavirus-infektvität |
DK1285080T3 (da) | 2000-05-31 | 2008-12-01 | Novartis Vaccines & Diagnostic | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
AU2001273313A1 (en) | 2000-07-07 | 2002-01-21 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU9322201A (en) | 2000-08-29 | 2002-03-13 | American Cyanamid Co | Packaging of positive-strand rna virus replicon particles |
AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
AU2002303330B2 (en) | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
JP4790984B2 (ja) * | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
AU2003222068A1 (en) | 2002-03-25 | 2003-10-13 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
JP3857195B2 (ja) | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
ES2618309T3 (es) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
DK2290054T3 (en) | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
KR101454842B1 (ko) | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
US7419674B2 (en) | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
-
2004
- 2004-07-08 US US10/886,773 patent/US7419674B2/en active Active
- 2004-07-08 DK DK04777706T patent/DK1651666T3/da active
- 2004-07-08 AU AU2004257214A patent/AU2004257214B2/en not_active Expired
- 2004-07-08 EP EP04777706A patent/EP1651666B1/de not_active Expired - Lifetime
- 2004-07-08 WO PCT/US2004/021772 patent/WO2005007689A1/en active Application Filing
- 2004-07-08 AT AT04777706T patent/ATE432285T1/de active
- 2004-07-08 ES ES04777706T patent/ES2327643T3/es not_active Expired - Lifetime
- 2004-07-08 DE DE602004021260T patent/DE602004021260D1/de not_active Expired - Lifetime
- 2004-07-08 PT PT04777706T patent/PT1651666E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
DE602004021260D1 (de) | 2009-07-09 |
EP1651666A1 (de) | 2006-05-03 |
AU2004257214B2 (en) | 2010-04-22 |
ES2327643T3 (es) | 2009-11-02 |
PT1651666E (pt) | 2009-08-28 |
EP1651666B1 (de) | 2009-05-27 |
US20050054107A1 (en) | 2005-03-10 |
AU2004257214A1 (en) | 2005-01-27 |
US7419674B2 (en) | 2008-09-02 |
ATE432285T1 (de) | 2009-06-15 |
WO2005007689A1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1651666T3 (da) | Alfavirus-baserede cytomegalovirusvacciner | |
DE60236864D1 (de) | Chimere alphavirus-replikon-partikel | |
HUP0301659A2 (hu) | Kukorica cellulóz-szintetázok és alkalmazásuk | |
AU2002252183A1 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
DE60135983D1 (de) | Verfahren zur reinigung von alphaviralen replikon partikeln | |
MY139031A (en) | Vaccine composition comprising virus-like particles of human papillomavirus | |
NO20040282L (no) | Hepatit C virus-polymerase-inhibitorer, samt anvendelse og fremgangsmåte for fremstilling derav og farmasøytisk preparat | |
EP1594536A4 (de) | Adjuvante influenza-vakzine | |
DK1516058T3 (da) | Rekombinante mæslingevira, som udtrykker epitoper på antigener af RNA-vira, samt anvendelse af de rekombinante vira til fremstilling af vacciner | |
GB0224396D0 (en) | Propagation of viruses through an information technology network | |
EP1623015A4 (de) | Ha1 des equine-2-influenzavirus exprimierender dna-impfstoff | |
IL200747A0 (en) | Subunits of the enteritis hemorrhagic virus fiber protein and uses thereof as vaccines | |
EP1575601A4 (de) | Rekombinanteimpfstoffviren, die il-15 exprimieren, sowie verfahren zu ihrer verwendung | |
AU2002339603A1 (en) | Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins | |
TW200508247A (en) | Sars | |
DK1412486T3 (da) | Fremgangsmåde til virusformering | |
WO2003072725A3 (en) | Recombinant negative strand virus rna expression systems and vaccines | |
GB2401280B (en) | Propagation of viruses through an information technology network | |
GB2401281B (en) | Propagation of viruses through an information technology network | |
CY1109206T1 (el) | gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ | |
WO2005012538A3 (en) | Accelerated vaccination | |
ATE408013T1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
AU2003258611A1 (en) | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines | |
ATE453708T1 (de) | Impfstoff gegen west nile virus | |
WO2007104263A8 (zh) | 一种乙型肝炎病毒疫苗增效蛋白及其基因 |